# **World Journal of Pharmaceutical Sciences**

ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Available online at: https://wjpsonline.com/ **Research Article** 



# Design and development of stealth liposomes for oral administration of poorly bioavailable drug

G. Manisha\*, GS Sharma, S. Raja Shekar, T. Rama Rao

Department of Pharmaceutics, CMR College of Pharmacy, JNTU, Hyderabad, India

Received: 06-03-2022 / Revised Accepted: 28-04-2022 / Published: 01-05-2022

# ABSTRACT

The aim of the present study was to formulate Stealth Liposomes containing Curcumin which are formulated by combinations of Cholesterol, Distearoylphosphatidylcholine, hydrogenated sovphosphotidylcholine to treat rheumatoid arthritis. Turmeric and especially its most active compound curcumin have many scientifically-proven health benefits. It's a potent antiinflammatory and help improve symptoms of Rheumatoid arthritis. Total 8 formulations were Cholesterol, Distearoylphosphatidylcholine, developed using hydrogenated soyphosphotidylcholine in various ratios by thin film hydration method & evaluated for Entrapment Efficiency, SEM, particle size and shape, FTIR studies, invitro dissolution studies. From the invitro studies we can say that as the cholesterol ratio increases, drug release rate is increased upto particular ratio. Among all the fomulations, F7 formulation shows best drug release of 92.62% by the end of 24 hours whereas all the other formulations did not release the drug more than F7. So F7 formulation was choosen as optimized formulation.

Keywords: Curcumin, Cholesterol, Distearoylphosphatidylcholine, hydrogenated soyphosphotidylcholine

# INTRODUCTION

# Traditional Medicine System

Traditional system of medication is one of the hundreds of years old practices and long serving partner to mankind in the battle against infection and in having a sound existence. Indigenous individuals have been utilizing the exceptional approach of their traditional system of medications for quite a long time and among the most eminent are the Chinese, Indian, African frameworks of drug. Traditional medicine refers to any ancient and cultural based healthcare practice differing from scientific medicine and is largely transmitted orally of communities different culture hv (Karunamoorthi K, et al., 2012). The World Health Organization (WHO) sees that it is hard to assign one definition to the wide scope of attributes and components of traditional medicine, yet that a working definition is basic. It thus concludes that the traditional medicines "(include) diverse health practices, approaches, knowledge and beliefs incorporating plant, animal and mineral based medicines, spiritual therapies, manual techniques

Address for Correspondence: G. Manisha, Department of Pharmaceutics, CMR College of Pharmacy, JNTU, Hyderabad, India; E-mail: manisha.gunda14@gmail.com

**How to Cite this Article:** G. Manisha\*, GS Sharma, S. Raja Shekar1, T. Rama Rao. Design and development of stealth liposomes for oral administration of poorly bioavailable drug. World J Pharm Sci 2022; 10(05): 44-51; https://doi.org/10.54037/WJPS.2022.100501

**Copyright:** 2022@ The Author(s). This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA), which allows re-users to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.

and exercises applied singularly or in combination to maintain well-being, as well as to treat, diagnose or prevent illness.

**Traditional System of Medicines** (Ravishankar, B Shukla, 2007)

Ayurveda, Unani, Homeopathy, Siddha

#### **Current Status of Herbal Medicine**

Currently more than 80% of the total population relies upon traditional and plant determined drug since, plants are a significant wellspring of medications and by and by about 25% of pharmaceutical medicines in the US contain at least one plant-derived ingredient. In the only remaining century, around 121 pharmaceutical products were defined dependent on the traditional knowledge acquired from different sources (Qazimajaz A, Molvikhurshid I., 2016),

#### **Curcuma longa (Turmeric)**

The name of the genus, Curcuma, is derived from the Sanskrit kuńkuma, alluding to both turmeric and saffron, utilized in India since ancient times. Turmeric (Curcuma longa) is a blooming plant of the ginger family, Zingiberaceae, the roots of which are utilized in cooking. The plant is rhizomatous, herbaceous and lasting and is local to the Indian subcontinent and Southeast Asia and requires temperatures somewhere in the range of 20 and  $30^{\circ}$ C (68 and 86 F) and a considerable amount of rainfall to flourish.

#### **Biological activities of curcumin**

- Anti-inflammatory property
- Antioxidant properties
- It acts on lymphocytes
- It acts on platelet aggregation
- Curcumin as an anti-carcinogenic agent in humans
- Wound-healing properties
- Diabetes
- Antiviral properties

#### Turmeric in traditional system of medicine

- Turmeric is a natural antiseptic and antibacterial agent, useful in disinfecting cuts and burns.
- Turmeric when combined with cauliflower, it has shown to prevent prostate cancer and stop the growth of existing prostate cancer.

### **Novel Drug Delivery System**

Clinical medicine possesses an extremely broad range of drug molecules currently in use, and new drugs are added to the list every year. One of the main goals of any treatment employing xenobiotics is to increase the therapeutic index of the drug while minimizing its side-effects. The clinical utility of most conventional chemotherapeutics is limited either by the inability to deliver therapeutic drug concentrations to the target tissues or by severe and harmful toxic effects on normal organs and tissues. Different approaches have been attempted to overcome these problems by providing "selective" delivery to the affected area; the ideal solution would be to target the drug only to those organs, tissues, or cells affected by the disease. Selected carriers, such as molecular conjugates and colloidal particulates, can be suitable for this purpose. Colloidal particulates result from physical incorporation of the drug into a particulate colloidal system such as liposomes. niosomes, micro- and nano-spheres, erythrocytes, and polymeric and reverse micelles. Among these carriers, liposomes have been most studied. Their attraction lies in their composition, which makes them biocompatible and biodegradable. They consist of an aqueous core entrapped by one or more bilayers composed of natural or synthetic lipids. Liposomes composed of natural phospholipids are biologically inert and weakly immunogenic, and they possess low intrinsic toxicity. Further, drugs with different lipophilicities can be encapsulated into liposomes: strongly lipophilic drugs are entrapped almost completely in the lipid bilayer, strongly hydrophilic drugs are located exclusively in the aqueous compartment, and drugs with intermediate easily partition between the lipid and aqueous phases, both in the bilayer and in the aqueous core (Lasic DD, et.al 1993, Allen TM, et.al 1994)

#### Concept of Stealth liposomes: -

As stated by Yuanpeng Zhang, In World war II NAZI German's bombed the British command centers and they were helpless as their RADAR failed to detect the Nazi's bombers. These bombers were stealth bombers which were designed by Germans, were made up of special materials and unique design. As the allies failed to tackle the stealth bombers they were helpless and so the command centers were destroyed to bits...the same concept were used in long circulatory liposomes. We need such a newly designed drug delivery system which delivers the killer bombs deep inside tumor cells and destroy them, just like the stealth bombers did or was intended to. Camouflaging the liposomes so as to fool phagocytes into ignoring thus became a key objective them of pharmaceutical chemists, hence The result of their efforts was a process known as PEGylation, i.e. Covering outer side of liposome with polymer, To phagocytes, this molecular "cloak" of water of hydration makes the PEGylated liposomes look like little watery bubbles rather than something edible, so they tend to leave them alone (Allen TM. et.al., 1994, Gabizon AA. Et.al., 2001).

#### MATERIALS AND METHOD

Turmeric, Distearoylphosphatidyl choline, Soya lecithin, Cholesterol, obtained from BMR Chemicals, Hyd, India. Chloroform, Methanol was procured from Narmada Chemicals, Hyd. Polyvinylpyrrolidone procured from Rankem, India.

# **Method of Preparation of Curcumin Loaded Stealth Liposomes:** (Amelia P, 2015, Mohamed M, 2016)

Accurate amount of Curcumin, Phospholipid and cholesterol were dissolved in little quantity of chloroform: Methanol (2:1) in a round bottom flask. The solvent was allowed to evaporate to form a thin film of lipid on the wall of flask. Lipid film was then hydrated with phosphate buffer of pH 7.4 by mechanical shaker for 1 h at Room temperature. The flask was rotated again at same speed and temperature as before, for the removal of lipid film from the walls and dispersion to from liposomes. To this suspension of conventional liposomes, 1 ml of 10 % w/v of PVP was added slowly under 100 r/min rotation for the preparation of stealth liposomes. Both the suspensions were then allowed to stand for 2-3 h for the complete swelling. Each batch was prepared similarly and was stored in the refrigerator in a suitable container.

 Table 1: A Composition of curcumin loaded

 stealth liposomes

Ingredients (mg)	F1	F2	F3	F4
Curcumin	100	100	100	100
Distearoylphosphatidyl choline	400	400	400	400
Soya lecithin	-	-	-	-
Cholesterol	50	100	150	200
Chloroform:Methanol (2:1)	Q.S	Q.S	Q.S	Q.S
Phosphate buffer	10	10	10	10
PVP (mL)	1	1	1	1

 Table 2: B Composition of curcumin loaded

 stealth liposomes

Ingredients (mg)	F5	F6	F7	F8
Curcumin	100	100	100	100
Distearoylphosphatidyl choline	-	-	-	-
Soya lecithin	400	400	400	400
Cholesterol	50	100	150	200
Chloroform:Methanol (2:1)	Q.S	Q.S	Q.S	Q.S
Phosphate buffer	10	10	10	10
PVP (mL)	1	1	1	1

**Evaluation Studies:** Zhengui Y, et.al, 2010, Okhil KN, et.al, 2013, Mali D, 2013, Narashimhan LR, et.al, 2012)

#### **Entrapment efficiency:**

The percentage drug entrapped was determined by centrifugation. Liposomal suspension was placed in the centrifugal tube and it was balanced on the other side with an equivalent weight. The centrifugation was carried out 1000 r/min for 60 min. The supernatant was removed and the concentration of the supernatant was determined spectrophotometrically at 421 nm. The percentage of drug entrapment was calculated using the equation,

#### Scanning electron microscopy:

The average size and size distribution of curcumin loaded stealth liposomes were determined by SEM, in which the samples were mounted rigidly on the surface of a bronze specimen holder called a specimen stub using a double sided adhesive tape and coated with an ultrathin coating of electricallyconducting material, gold, deposited on the sample either by low vacuum sputter coating or by high vacuum evaporation with gold and observed under suitable magnification.

#### **FTIR Studies:**

Infrared spectroscopy lies more in the qualitative identification of substances either in pure form or in the mixture and as a tool in establishment of the structure. The infrared data is helpful to confirm the identity of the drug and to detect the interaction of the drug with the polymers. Infrared spectra of extract and polymers, alone and in physical mixtures were taken. Then it was investigated for any possible interaction between polymer and the drug.

#### Particle size and shape

The size of particles and their distribution were determined using Zetasizer (Nano ZS Malvern Instruments, UK) using a process called dynamic light scattering (DLS). Samples were examined to determine the mean particle size, size distribution, and polydispersity index (PDI). This technique measures the time-dependent fluctuations in the intensity of scattered light, which occurs because the particles are under Brownian motion. Analysis of these intensity fluctuations enables the determination of the diffusion coefficient of the particles, which are converted into the size distribution.

#### Zeta potential:

There are three ways by which a solid particle (colloid) dispersed in a liquid media can acquire a surface charge. First, by the adsorption of ions present in the solution. Second, by the ionization of functional groups on the particle's surface. Third, due to the difference in dielectric constant between the particle and the medium. Attention should be paid to the formation of electric double layer at the solid-liquid interface. The zeta Potential is defined as the difference in potential between the surface of the tightly bound layer (shear plane) and the electro-neutral region of the solution. The potential gradually decreases as the distance from the surface increases.

As the concentration of electrolyte increases in the medium, the zeta potential falls off rapidly due to the screening effect of the counter ions. The zeta potential cannot be measured directly; however, it can be calculated using theoretical models and from experimentally determined electrophoretic mobility data. The theory is based on electrophoresis and can be expressed as:

#### $\mu = \zeta \epsilon / \eta$

Where  $(\mu)$  is the electrophoretic mobility, $(\epsilon)$  is the electric permittivity of the liquid, $(\eta)$  Is the viscosity and  $(\zeta)$  us the zeta potential.

#### In-vitro drug diffusion


The release studies were carried out in 250 ml beaker containing 100 ml Phosphate buffer. Phosphate buffer pH 7.4 (100 ml) was placed in a 250 ml beaker. The beaker was assembled on a magnetic stirrer and the medium was equilibrated at 37±0.5°C. Dialysis membrane was taken and one end of the membrane was sealed. 20mg weight equivalent Curcumin loaded stealth liposomal dispersion was filled in the dialysis membrane and other end was closed. The dialysis membrane containing the sample was suspended in the medium. 5ml of aliquots were withdrawn at specific intervals, filtered after withdrawal and the apparatus was immediately replenished with same quantity of fresh buffer medium. The Aliquots was measured for the amount of the drug by using UV spectrophotometer at 421nm.

#### **Kinetic studies:**

To analyze the mechanism of release and release rate kinetics of the dosage form, the data obtained were fitted into Zero order, First order, Higuchi matrix, Peppas models. Based on the r-value, the best-fit model was selected.

#### **RESULTS AND DISCUSSION**


#### Evaluation studies: Particle size analysis:



# Fig 1: Particle size analysis

**Discussion:** Average particle size of curcumin loaded stealth liposomes of optimized formulations (F7) was found to be 179.5 nm.

#### Scanning electron microscopy:



**Fig 2: SEM analysis of Curcumin loaded stealth liposomes of optimized formulation (F7) Discussion:** SEM analysis revealed that Nanosized spherical particles with numerous pores on surface.

**Entrapment efficiency:** -The entrapment efficacy of the formulated stealth liposomes was found to be in the range of 76.32±1.02%-96.13±0.94% respectively.

Formulation code	
coue	Entrapment efficacy ± S.D
F1	93.16±0.54
F2	95.42±1.34
F3	76.32±1.02
F4	87.42±0.89
F5	96.13±0.94
F6	95.24±0.65
F7	91.16±1.04
F8	86.31±0.31

 Table 3: Entapment efficiency

**Discussion:** Formulation F3 & F5 were obtained good results in entrapment efficiency with  $76.32\pm1.02$  and  $96.13\pm0.94$ .

#### In-vitro drug release studies:

Table4:In-vitrodrugreleasedataofformulation (F1-F4)

	Cummulative Percentage release			Drug
Time (hrs)	F1	F2	F3	F4
0	0	0	0	0
2	12.64±	16.34±	23.06±	29.34±
	0.12	0.69	0.02	0.16
4	26.34±	29.31±	39.64±	35.62±
	0.35	0.45	0.34	0.21
6	32.05±	41.05±	46.21±	40.15±
	0.64	0.31	0.68	0.18
8	43.16±	49.37±	56.32±	46.31±
	0.78	0.02	0.75	0.52
10	51.05±	56.28±	62.25±	54.13±
	0.52	0.74	0.24	0.36
12	59.67±	61.79±	69.73±	61.08±
	0.02	0.52	0.01	0.02
16	65.24±	73.16±	75.32±	69.31±
	0.69	0.31	0.36	0.21
20	$70.32\pm 0.35$	85.39± 0.46	82.04± 0.29	75.32± 0.64
24	79.34±	92.34±	86.31±	79.31±
	1.01	0.12	0.25	0.39

Table 5: In-vitro drug release data offormulation (F5-F8)

Tormula	Cummulative Percentage Drug				
Time	release				
(hrs)	F5	F6	F7	F8	
0	0	0	0	0	
2	22.04±	16.32±	13.06±0	20.31±	
	0.42	0.36	.26	0.26	
4	39.64±	29.34±	22.18±0	36.12±	
	0.36	0.13	.42	0.41	
6	52.03± 0.15	$39.25 \pm 0.02$	36.01±0 .86	46.31± 0.53	
8	63.13±	53.12±	49.21±0	54.05±	
	0.78	0.69	.312	0.52	
10	72.02±	61.05±	58.15±0	59.36±	
	0.96	0.78	.21	0.14	
12	78.14±	72.32±	71.02±0	65.13±	
	0.32	0.15	.56	0.26	
16	82.05±	81.09±	79.02±0	71.05±	
	0.02	0.34	.93	0.37	
20	86.31±	86.32±	85.31±0	82.31±	
	0.64	0.26	.78	0.14	
24	89.52±	92.15±	97.02±0	87.26±	
	0.12	0.36	.24	0.26	

**Discussion:** From the above invitro studies we can say that as the cholesterol ratio increases, drug release rate is increased upto particular ratio. Among all the fomulations, F7 formulation shows best drug release of 97.02% by the end of 24 hours where as all the other formulations did not release the drug more than F7.

Because F7 formulation having hydrogenated soya phosphatidyl choline with cholesterol at 3:1 ratio shows better drug release then the other concentrations.




Fig 3: In-vitro drug release for all the formulations (F1-F8)




Fig 4: In-vitro drug release of formulations F1-F4




Fig 5: In-vitro drug release of formulations F5-F8

Drug release kinetics: Table 6: Drug release kinetics data of optimized formulation (F7)


Time (hrs)	% CDR	%Drug Remaining	Square Root Time
0	0	100	0
2	13.06	86.94	1.414
4	22.18	77.82	2
6	36.01	63.99	2.449
8	49.21	50.79	2.828
10	58.15	41.85	3.162
12	71.02	28.98	3.464
16	79.02	20.98	4
20	85.31	14.69	4.472
24	97.02	2.98	4.899


Table 3.2.1-B: Drug release kinetics data ofoptimized formulation (F7)

Time (hrs)	Log Cummulativ e % Drug Remaining	Log Time	Log % CDR
0	2	0	0
2	1.939	0.301	1.116
4	1.891	0.602	1.346

6	1.806	0.778	1.556
8	1.706	0.903	1.692
10	1.622	1	1.765
12	1.462	1.079	1.851
16	1.322	1.204	1.898
20	1.167	1.301	1.931
24	0.474	1.380	1.987










Fig 7: First order graph of optimized formulation






Fig 8: Higuchi graph of optimized formulation

49




Fig 9: Peppas graph of optimized formulation

#### DISCUSSION

The invitro dissolution data for best formulation F7 were fitted in different kinetic models i.e, zero order, first order, Higuchi and korsemeyer-peppas equation. Optimized formulation F7 shows  $R^2$  value 0.942. As its value nearer to the '1' it is conformed as it follows the First order release. The mechanism of drug release is further confirmed by the korsmeyer and peppas plot, if n = 0.45 it is called Case I or Fickian diffusion, 0.45 < n < 0.89 is for anomalous behavior or non-Fickian transport, n = 0.89 for case II transport and n > 0.89 for Super case II transport.

#### CONCLUSION

Stealth liposomes containing curcumin was developed by using combination of cholesterol, Distearorylphosphatidyl choline, soya lecithin & PVP to treat rheumatoid arthritis. FTIR spectroscopic studies designate that are no drugexcepient interaction Average PS of curcumin loaded stealth liposomes of optimized formulation (F6) was found to be 179.5 nm. Zeta potential value for the optimized formulation (F7) was found to be within the acceptable limits.

From the above invitro studies we can say that as the cholesterol ratio increases, drug release rate is increased upto particular ratio. Among all the fomulations, F7 formulation shows best drug release of 97.02% by the end of 24 hours where as all the other formulations did not release the drug more than F7.

# REFERENCES

- Karunamoorthi K, Tamil traditional medicine system – Siddha: an indigenous health practice in the international perspectives. International journal of Genuine Traditional Medicine., (2012), 2(2).
- 2. Ravishankar, B Shukla, Indian Systems of Medicine: A Brief Profile Complementary And Alternative Medicines V.J. African Journal of Traditional medicine. Cam, (2007), 4 (3).

- 3. Qazimajaz A, Molvikhurshid I., Herbal medicine: a comprehensive review. International journal of pharmaceutical research, (2016).
- 4. curcumin in animals. Wound Repair and Regeneration., pp 6: 167.
- Thaloor, D, et al., Systemic administration of the NF-kappa B inhibito curcumin stimulates muscle regeneration after traumatic injury. American Journal of Physiology, (1999).
- 6. Babu. P.S. and Srinivasan. KInfluence of dietary curcumin and cholesterol in the progression of experimentally induced diabetes in albino rat. Molecular and Cellular Biochemistry, pp, (1995).
- Babu. P.S. and Srinivasan. K, Hypolipidemic action of curcumin, the active principle of turmeric (Curcuma longa) in streptozotocin induced diabetic rats. Molecular and Cellular Biochemistry, (1997).
- 8. Bourne, K.Z. Bourne., Plant products as topical microbicide candidates: Assessment of in vitro and in vivo activity against herpes simplex virus type 2. Antiviral Research, pp (1999).
- 9. Mazumder, A., Inhibition of Human Immunodeficiency Virus Type-1 Integrase by curcumin. Biochemical. Pharmacology, (1995), 49(8).
- 10. researchgate.net/publication/268268687\_T urmeric\_A\_Herbal\_and\_Traditional\_Medi cine.
- 11. Lasic DD, Winterhalter M. Liposome stability and formation: Experimental parameters and theories on the size distribution, Chemistry and physics of lipids, 1993); 64(1) :35-43
- 12. Allen TM. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends in pharmaceutical sciences, 1994; 15(7):215-220
- 13. Gabizon AA. Stealth liposomes and tumor targeting: One step further in the quest for the magic bullet, Clinical cancer research, 2001;7:223
- 14. Gabizon AA. PEGylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy, informa healthcare, 2001;19(4):424-436
- Woodle MC, Collins LR, Sponsler E, Kossovosky N, Martin FJ. Sterically stabilized liposomes. Journal of biophysical society, 1992;61: 902-910.
- Demirgo D, Garg A and Kokkoli E. PRb-Targeted PEGylated Liposomes for prostate cancer therapy. 2008; 24(23).

- Srinath P, Diwan PV. Stealth liposomes: An overview", Indian journal of pharmacology, 1994.
- 18. Immordino ML, Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs.
- Amelia P, Andrea M, Vincenzo T, Anna M, Paolo N Guendalina Z. Preparation, characterization and in vitro evaluation of sterically stabilized liposome containing a naphthalenediimide derivative as anticancer agent. Drug Deliv. 2015, 22(5), 590-597.
- Zhengui Y, Dawei C, Shoutang Z, Zhendong Z. Preparation, characetrizarion and evaluation of docetaxel-loaded folate conjugated PEG-liposomes. The Pharmaceutical society of Japan. 2010, 130(10).
- 21. Okhil KN, Vivek RY, Andria H, Vibhudutta A. Post-modification of preformed liposomes with novel nonphospholipid poly (ethylene glycol)conjugated hexadecylcarbamoylmethylhexadecanoic acid for enhanced circulation persistence in vivo. Int J Pharm. 2013, 446. 119-129.
- 22. Mali D, Nanjwade B, Manvi FV. Formulation and Characterization of Tamoxifen Loaded Stealth Liposomes for Breast cancer. Int. J. drug dev.res. 2013, 5(1), 271-278.
- Alina P, Loan T, Dana M, Lavinia L. Optimizing long-circulating liposomes for delivery of simvastatin to C26 colon carcinoma cells. J Liposome Res. 2014, 1-9.
- 24. Lucia RT, Bianca S, Ioan T, Alina S. Development of antiproliferative longcirculating liposomes co-encapsulating doxorubicin and curcumin, through the use of a quality-by-design approach. Drug Des, Dev and Ther. 2017, 11, 1605-1621.
- 25. Mohamed M, Piwoni A, Filickzak N, Janicka M, Gubernator J. Long-circulating curcumin-loaded liposome formulations with high incorporation efficiency, stability and anticancer activity towards pancreatic adenocarcinoma cell lines in vitro. PLoS One 2016, 12(3).
- Narashimhan LR, Shilpee S, Swaminathan S, Udaykumar R, Krishnan UM, Investigation on the stability of saquinavir loaded liposomes: implication on stealth, release characteristics and cytotoxicity. Int J Pharm, (2012) 431(1–2):120–129.